Sort
48,018 grants matching “immunotherapy”
Dendritic Cell/Leukemia Fusions and PD-1 Blockade for AML
$379,018Jacalyn Rosenblatt · Beth Israel Deaconess Medical Center · R21 · FY2010 · CA
Inhibiting mitochondrial complex I to improve cetuximab efficacy in oral cancer
$378,951Yong Teng · Emory University · R01 · FY2025 · DE
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2021 · NS
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2020 · NS
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2022 · NS
Targeting CCR2-expressing myeloid cells to overcome immune checkpoint inhibitor resistance in glioma
$378,934Jeffrey K Harrison · University Of Florida · R01 · FY2019 · NS
Immunomodulation of breast cancer via TLR7 agonist imiquimod and radiotherapy.
$378,909Silvia C Formenti · New York University School Of Medicine · R01 · FY2011 · CA
Applying deep learning to predict T cell receptor binding specificity of neoantigens and response to checkpoint inhibitors
$378,897Tao Wang · Ut Southwestern Medical Center · R01 · FY2021 · CA
Immunomodulatory Effects of Heterochiral Biomaterials
$378,885Jai Rudra · Washington University · R01 · FY2019 · AI
A Pathway for Necrotic Cell Death
$378,867David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2022 · CA
A Pathway for Necrotic Cell Death
$378,867David J Shapiro · University Of Illinois At Urbana-Champaign · R01 · FY2023 · CA
Correlative Studies and Immune Monitoring Core
$378,857Kent J. Weinhold · Duke University · P01 · FY2018 · CA
Tumor-intrinsic signaling pathways restrict anti-tumor immunity in hepatocellular carcinoma
$378,856Amaia Lujambio · Icahn School Of Medicine At Mount Sinai · R37 · FY2023 · CA
Microparticle Therapy for Cerebral Amyloid Angiopathy
$378,841Wolff M. Kirsch · Karamedica, Inc. · R43 · FY2018 · AG
Mechanisms of the induction of oral tolerance
$378,809Howard L Weiner · Brigham And Women'S Hospital · R01 · FY2009 · AI
Mechanisms of the induction of oral tolerance
$378,809Howard L Weiner · Brigham And Women'S Hospital · R01 · FY2008 · AI
Characterization of Fuctional Defective Autoimmune Human CD4+CD25+ Tregs
$378,794David A. Hafler · Brigham And Women'S Hospital · U19 · FY2007 · AI
CYTOGENETICS AND BIOCHEMISTRY OF PROSTATE CANCER
$378,787Case Western Reserve University · R01 · FY2002 · CA
3D biomimetic lymph node engineered extracellular vesicles for understanding the heterogeneity of adaptive immunity
$378,750Mei He · University Of Kansas Lawrence · R35 · FY2019 · GM
Immune activation by cetuximab in head and neck cancer patients
$378,750Robert L Ferris · University Of Pittsburgh At Pittsburgh · R01 · FY2010 · DE
Augmentation of GVL Reactivity Without GVHD
$378,750William R. Drobyski · Medical College Of Wisconsin · R01 · FY2010 · HL
Immune Response to Cat: Regulatory and Effector T Cells
$378,750Judith A Woodfolk · University Of Virginia · R01 · FY2009 · AI
Immunization Strategies for Autologous HIV Immunotherapy
$378,750Louis D Falo · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · AI
Nutrient sensing ghrelin signaling - a novel pathogenic factor for Alzheimerâs Disease
$378,750Yuxiang Sun · Texas A&M Agrilife Research · R01 · FY2021 · AG
Mechanisms of Immune Evasion by Ocular Tumors
$378,750Kyle C McKenna · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · EY